2Koning GA,Morselt HW,Gorter A,et al.Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells:an in vitro comparison.Pharm Res,2003,20:1249-1257.
3Viglianti BL,Abraham SA,Michelich CR,et al.In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI:illustration of targeted delivery.Magn Reson Med,2004,51:1153-1162.
4Ono A,Takeuchi K,Sukenari A,et al.Reconsideration of drug release from temperature-sensitive liposomes.Biol Pharm Bull,2002,25:97-101.
5Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer J Clin, 2011,61:134.
6Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase NO. 10. Lyon, France: International Agency for Research on Cancer; Year. Available at : http ://globacan. iarc. ft. 2010.
7Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial. Lancet Oncology, 2009,10:25-34.
